High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.

Peter Hillmen, Arnon P Kater, John Francis Seymour, Anton W Langerak, Barbara Eichhorst, Carolyn Owen, Sarit E Assouline, Ann Janssens, Paula Marlton, Xavier C Badoux, Rogier Mous, Brenda Chyla, Rod Humerickhouse, Michelle Boyer, Kathryn Humphrey, Yanwen Jiang, Elizabeth Punnoose, Jue Wang, Qun Jenny Wu, Mehrdad Mobasher